Precision Cardiovascular Appoints Matthew I. Mace to Board of Directors, Bolstering Clinical and Regulatory Leadership

Matthew has over 15 years of specialised experience in both invasive and non-invasive cardiovascular technologies: Matthew has over 15 years of specialised experience in both invasive and non-invasive cardiovascular technologies: A Strategic Addition to PCV's Board "Precision Cardiovascular stands at a key moment, bridging cutting-edge research with real-world clinical impact," saidMatthew Mace. "Leveraging my experience in both implantable devices and AI-driven haemodynamic...

Matthew has over 15 years of specialised experience in both invasive and non-invasive cardiovascular technologies:

A Strategic Addition to PCV's Board

"Precision Cardiovascular stands at a key moment, bridging cutting-edge research with real-world clinical impact," said Matthew Mace. "Leveraging my experience in both implantable devices and AI-driven haemodynamic monitoring aligns perfectly with the Company's mission to redefine cardiac care. I'm honoured to contribute to its journey toward clinical validation and global adoption."

CEO Mohamed Abou-Alam highlighted the significance of the appointment: "Matthew's dual expertise in traditional cardiac devices and ML-driven solutions accelerates our ability to navigate complex regulatory landscapes. His guidance will be instrumental as we advance our pipeline into clinical trials next year, ensuring our innovations meet the highest standards of safety and efficacy."

Strengthening Leadership as PCV Advances Toward Clinical Trials

Matthew's appointment comes at a pivotal time as Precision Cardiovascular expands its pre-clinical work in minimally invasive haemodynamic monitoring. The Company aims to initiate first-in-human trials for its flagship sensor technology in 2026.

About Precision Cardiovascular

Precision Cardiovascular develops novel remote monitoring solutions for heart failure management. Its pipeline integrates advanced sensor technology with machine learning to enable reliable and proactive cardiac care in everyday settings. The Precision Cardiovascular system is currently investigational and not cleared for clinical use in any geography.

Media Contact:
Precision Cardiovascular, The Magdi Yacoub Institute, Heart Science Centre, Harefield Hospital
Email:[email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/precision-cardiovascular-appoints-matthew-i-mace-to-board-of-directors-bolstering-clinical-and-regulatory-leadership-302375998.html